Search This Blog

Wednesday, August 5, 2026

AbCellera revenue falls to $4.1M, $55.4M net loss, secures >$100M upfront cash from Jazz, Vertex

 


  • Upfront payments relate to T‑cell engager collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals.
  • Company ended the quarter with more than $675 million in available liquidity.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)